# GBP2 promotes podocyte pyroptosis and contributes to the pathogenesis of pediatric lupus nephritis

**Authors:** Yu Sun, Jiahui Wei, Yanjun Zhao, Xingbo Jiang, Chao He, Xianhui Huang, Fengying Lei, Yuanhan Qin

PMC · DOI: 10.1371/journal.pone.0344601 · PLOS One · 2026-03-19

## TL;DR

GBP2 promotes kidney cell death in children with lupus nephritis, contributing to disease progression through inflammation.

## Contribution

GBP2 is identified as a novel driver of podocyte pyroptosis in pediatric lupus nephritis.

## Key findings

- GBP2 and GSDMD are upregulated in glomeruli of children with lupus nephritis.
- GBP2 knockdown reduces pyroptosis and inflammatory cytokine release in podocytes.
- GBP2 overexpression worsens pyroptosis and inflammation, which is partially reversed by AIM2 overexpression.

## Abstract

Lupus nephritis (LN), a prevalent and serious manifestation of systemic lupus erythematosus, exhibits particularly high incidence in children, yet its pathogenesis remains incompletely elucidated. This study aimed to investigate differentially expressed genes in LN and elucidate their regulatory mechanisms.

Bioinformatics analysis was conducted on the publicly available glomerular gene expression dataset GSE32591 from the Gene Expression Omnibus to identify hub genes. Based on this screening, Guanylate-binding protein 2 (GBP2) was selected for further investigation. In vivo, GBP2 expression was assessed in renal tissues from pediatric LN patients by immunohistochemistry. In a murine LN model, the expression levels of GBP2 and key pyroptosis-associated markers were evaluated using immunohistochemistry, RT-qPCR, and western blotting. In vitro, a podocyte pyroptosis model was induced by lipopolysaccharide and adenosine triphosphate treatment. Functional experiments involving Gbp2 knockdown and overexpression, followed by a rescue experiment where absent in melanoma 2 (Aim2) was overexpressed in Gbp2-knockdown cells, were performed to elucidate its role and underlying mechanisms in regulating pyroptosis.

Bioinformatics analysis identified OAS1, OAS2, IRF7, GBP2, and GBP1 as hub genes. An upregulation of GBP2 and gasdermin D (GSDMD) was observed in the glomeruli of children with LN, showing a strong correlation with 24-hour urinary protein excretion. Renal tissues from LN mice exhibited markedly increased expression of GBP2, AIM2, Caspase-1, and GSDMD compared to controls. Following siRNA-mediated knockdown of Gbp2 in vitro, a consequent reduction was observed in pyroptosis-associated proteins (GSDMD, AIM2) and diminished secretion of the pro-inflammatory cytokines IL-1β and IL-18. Conversely, Gbp2 overexpression aggravated these effects. Pyroptosis suppressed by Gbp2 knockdown was partially restored upon concurrent overexpression of Aim2.

Our results demonstrate that GBP2 expression is significantly upregulated in LN and promotes podocyte pyroptosis, likely contributing to renal injury. These findings suggest that GBP2 facilitates the progression of pediatric LN by activating the pyroptotic pathway and triggering the release of inflammatory cytokines.

## Linked entities

- **Genes:** GBP2 (guanylate binding protein 2) [NCBI Gene 2634], GSDMD (gasdermin D) [NCBI Gene 79792], AIM2 (absent in melanoma 2) [NCBI Gene 9447], OAS1 (2'-5'-oligoadenylate synthetase 1) [NCBI Gene 4938], OAS2 (2'-5'-oligoadenylate synthetase 2) [NCBI Gene 4939], IRF7 (interferon regulatory factor 7) [NCBI Gene 3665], GBP1 (guanylate binding protein 1) [NCBI Gene 2633]
- **Proteins:** GBP2 (guanylate binding protein 2), GSDMD (gasdermin D), AIM2 (absent in melanoma 2), Caspase1 (caspase-1), IL1B (interleukin 1 beta), IL18 (interleukin 18)
- **Diseases:** lupus nephritis (MONDO:0005556), systemic lupus erythematosus (MONDO:0007915)
- **Species:** Homo sapiens (taxon 9606), Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** Gapdh (glyceraldehyde-3-phosphate dehydrogenase) [NCBI Gene 14433] {aka Gapd}, CASP1 (caspase 1) [NCBI Gene 834] {aka ICE, IL1BC, P45}, TMEM132A (transmembrane protein 132A) [NCBI Gene 54972] {aka GBP, HSPA5BP1}, OAS2 (2'-5'-oligoadenylate synthetase 2) [NCBI Gene 4939] {aka AIAISD2}, GBP5 (guanylate binding protein 5) [NCBI Gene 115362] {aka GBP-5}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, NOTCH1 (notch receptor 1) [NCBI Gene 4851] {aka AOS5, AOVD1, TAN1, hN1}, Casp8 (caspase 8) [NCBI Gene 12370] {aka CASP-8, FLICE, MACH, Mch5}, AIM2 (absent in melanoma 2) [NCBI Gene 9447] {aka PYHIN4}, Gbp2 (guanylate binding protein 2) [NCBI Gene 14469], Aim2 (absent in melanoma 2) [NCBI Gene 383619] {aka Gm1313, Ifi210}, IRF7 (interferon regulatory factor 7) [NCBI Gene 3665] {aka IMD39, IRF-7, IRF-7H, IRF7A, IRF7B, IRF7C}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, GBP3 (guanylate binding protein 3) [NCBI Gene 2635], GBP2 (guanylate binding protein 2) [NCBI Gene 2634], OAS1 (2'-5'-oligoadenylate synthetase 1) [NCBI Gene 4938] {aka E18/E16, IFI-4, IMD100, OIAS, OIASI}, NLRP3 (NLR family pyrin domain containing 3) [NCBI Gene 114548] {aka AGTAVPRL, AII, AVP, C1orf7, CIAS1, CLR1.1}, Il1b (interleukin 1 beta) [NCBI Gene 16176] {aka IL-1beta, Il-1b}, GSDMD (gasdermin D) [NCBI Gene 79792] {aka DF5L, DFNA5L, FKSG10, GSDMDC1}, Nlrp3 (NLR family, pyrin domain containing 3) [NCBI Gene 216799] {aka AGTAVPRL, AII/AVP, Cias1, FCAS, FCU, MWS}, Il18 (interleukin 18) [NCBI Gene 16173] {aka Igif, Il-18}, ATN1 (atrophin 1) [NCBI Gene 1822] {aka B37, CHEDDA, D12S755E, DRPLA, HRS, NOD}, Gsdmd (gasdermin D) [NCBI Gene 69146] {aka 1810036L03Rik, DF5L, Dfna5l, GsdmD-1, Gsdmdc1, M2-4}, Casp1 (caspase 1) [NCBI Gene 12362] {aka ICE, Il1bc}, CXCL8 (C-X-C motif chemokine ligand 8) [NCBI Gene 3576] {aka GCP-1, GCP1, IL8, LECT, LUCT, LYNAP}, GBP1 (guanylate binding protein 1) [NCBI Gene 2633] {aka hGBP1}, IL18 (interleukin 18) [NCBI Gene 3606] {aka IGIF, IL-18, IL-1g, IL1F4}
- **Diseases:** COVID-19 (MESH:D000086382), inflammation (MESH:D007249), renal failure (MESH:D051437), renal tumors (MESH:D007680), nephrotic syndrome (MESH:D009404), Staphylococcus aureus infection (MESH:D013203), 1C (MESH:C536486), renal clear cell carcinoma (MESH:D002292), membranous nephropathy (MESH:D015433), tumor (MESH:D009369), tuberculosis (MESH:D014376), diabetic nephropathy (MESH:D003928), glomerular damage (MESH:D007674), EB virus infection (MESH:D014777), LN (MESH:D008181), SLE (MESH:D008180), autoimmune disorder (MESH:D001327), bleeding (MESH:D006470), GSDMD (MESH:D014808), infections (MESH:D007239), herpes simplex virus 1 infection (MESH:D006561), Proteinuria (MESH:D011507), metabolic abnormalities (MESH:D008659), coronavirus disease (MESH:D018352)
- **Chemicals:** xylene (MESH:D014992), AP (MESH:D000667), alcohols (MESH:D000438), SDS (MESH:D012967), urea nitrogen (MESH:C530477), CO2 (MESH:D002245), hematoxylin (MESH:D006416), LPS (MESH:D008070), ATP (MESH:D000255), H2O2 (MESH:D006861), pentobarbital sodium (MESH:D010424), guanosine triphosphate (MESH:D006160), citrate (MESH:D019343), formalin (MESH:D005557), PVDF (MESH:C024865), creatinine (MESH:D003404), A6419 (-), paraffin (MESH:D010232)
- **Species:** Influenza A virus (no rank) [taxon 11320], Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]
- **Cell lines:** C57BL/6J — Mus musculus (Mouse), Transformed cell line (CVCL_C0MW), MPC-5 — Mus musculus (Mouse), Conditionally immortalized cell line (CVCL_AS87), MRL/lpr — Mus musculus (Mouse), Stromal cell line (CVCL_B6HA)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13001939/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13001939/full.md

## References

39 references — full list in the complete paper: https://tomesphere.com/paper/PMC13001939/full.md

---
Source: https://tomesphere.com/paper/PMC13001939